Efficacy and acceptability of neoadjuvant endocrine therapy in patients with hormone receptor‐positive breast cancer: A network meta‐analysis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy and acceptability of neoadjuvant endocrine therapy in patients with hormone receptor‐positive breast cancer: A network meta‐analysis

Published:2019-01-16 Issue:8 Volume:234 Page:12393-12403
ISSN:0021-9541
Container-title:Journal of Cellular Physiology
language:en
Short-container-title:J Cell Physiol

Author:

Zhang Tingting¹,Feng Fubin²,Yao Yan³,Qi Lingyu⁴,Tian Jinhui⁵,Zhou Chao²,Dong Shengjie⁶,Wang Xue⁷,Sun Changgang²⁸^ORCID

Affiliation:

1. College of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine Jinan Shandong People's Republic of China

2. Department of Oncology Weifang Traditional Chinese Hospital WeiFang Shandong People's Republic of China

3. Clinical Medical Colleges, Weifang Medical University WeiFang Shandong People's Republic of China

4. College of First Clinical Medicine, Shandong University of Traditional Chinese Medicine Jinan People's Republic of China

5. Evidence‐Based Medicine Center, School of Basic Medical Sciences, Lanzhou University Lanzhou Gansu People's Republic of China

6. Department of the Joint and Bone Surgery Yantaishan Hospital Yantai Shandong People's Republic of China

7. Clinical Medical Colleges, Qingdao University Qingdao Shandong People's Republic of China

8. Department of Oncology Affiliated Hospital of Weifang Medical University Weifang Shandong People's Republic of China

Funder

National Natural Science Foundation of China

Publisher

Wiley

Subject

Cell Biology,Clinical Biochemistry,Physiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jcp.28068

Reference41 articles.

1. Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study

2. Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast Cancer

3. Sequential Preoperative or Postoperative Docetaxel Added to Preoperative Doxorubicin Plus Cyclophosphamide for Operable Breast Cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27

4. The Effect on Tumor Response of Adding Sequential Preoperative Docetaxel to Preoperative Doxorubicin and Cyclophosphamide: Preliminary Results From National Surgical Adjuvant Breast and Bowel Project Protocol B-27

5. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of neoadjuvant therapy for HR-positive/HER2-negative early breast cancer: a Bayesian network meta-analysis;Expert Review of Anticancer Therapy;2024-05-17

2. Effect of online interventions on reducing anxiety and depression for women with breast cancer: a systematic review and network meta-analysis protocol;BMJ Open;2023-07

3. Neoadjuvant endocrine therapy with or without palbociclib in low-risk patients: a phase III randomized double-blind SAFIA trial;Journal of Cancer Research and Clinical Oncology;2023-01-21

4. Cyclin-dependent kinase 4 and 6 inhibitors in combination with neoadjuvant endocrine therapy in estrogen receptor-positive early breast cancer: a systematic review and meta-analysis;Clinical and Experimental Medicine;2022-03-19

5. A Canadian national guideline on the neoadjuvant treatment of invasive breast cancer, including patient assessment, systemic therapy, and local management principles;Breast Cancer Research and Treatment;2022-02-28

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3